St. Louis encephalitis laboratory findings

St. Louis encephalitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating St. Louis encephalitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
St. Louis encephalitis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of St. Louis encephalitis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on St. Louis encephalitis laboratory findings
CDC on St. Louis encephalitis laboratory findings
St. Louis encephalitis laboratory findings in the news
Blogs on St. Louis encephalitis laboratory findings
Directions to Hospitals Treating St. Louis encephalitis
Risk calculators and risk factors for St. Louis encephalitis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Vishnu Vardhan Serla M.B.B.S. [2]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

In acute SLEV neuroinvasive disease cases, cerebrospinal fluid (CSF) examination shows a moderate (typically lymphocytic) pleocytosis. CSF protein is elevated in about a half to two-thirds of cases. SLEV is difficult to isolate from clinical samples and almost all isolates have come from brain tissue or CSF. In the absence of a sensitive and non-invasive virus detection method, serologic testing is the primary method for diagnosing SLEV infection. Combined with a consistent clinico-epidemiologic presentation, a rapid and accurate diagnosis of acute neuroinvasive SLEV disease can be made by the detection of SLEV-specific IgM antibody in serum or CSF. SLEV IgM tests are available commercially, in some state health department laboratories, and at CDC. A positive SLEV IgM test result should be confirmed by neutralizing antibody testing of acute- and convalescent-phase serum specimens at a state public health laboratory or CDC. To submit specimens for testing at CDC, contact your state health department. All SLEV disease cases should be reported to local public health authorities.